deltatrials
Recruiting PHASE4 INTERVENTIONAL 2-arm NCT06610760

Efficacy and Safety of Ursodeoxycholic Acid in Reversing Gastric Intestinal Metaplasia

Efficacy and Safety of Ursodeoxycholic Acid in Reversing Gastric Intestinal Metaplasia: A Multicenter, Randomized, Placebo-Controlled Trial

Sponsor: Yongquan Shi

Conditions Gastric Intestinal Metaplasia
Interventions Placebo Ursodeoxycholic Acid
Updated 3 times since 2024 Last updated: Dec 4, 2025 Started: Nov 12, 2024 Primary completion: Oct 31, 2026 Completion: Oct 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06610760, this PHASE4 trial focuses on Gastric Intestinal Metaplasia and remains actively recruiting participants. Sponsored by Yongquan Shi, it has been updated 3 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Oct 2024 – ~Aug 2025 · 10 months · monthly snapshotNot Yet Recruiting~Aug 2025 – ~Jan 2026 · 5 months · monthly snapshotRecruiting~Jan 2026 – present · 5 months · monthly snapshotRecruiting

Change History

3 versions recorded

  1. Jan 2026 — Present [monthly]

    Recruiting PHASE4

  2. Aug 2025 — Jan 2026 [monthly]

    Recruiting PHASE4

    Status: Not Yet Recruiting → Recruiting

  3. Oct 2024 — Aug 2025 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Yongquan Shi
Data source: Xijing Hospital of Digestive Diseases

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations